See the DrugPatentWatch profile for cosentyx
The impact of Cosentyx, a biologic medication used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis, on COVID-19 vaccine response is a topic of growing concern. While there is limited research on the subject, available studies suggest that Cosentyx may affect the immune response to COVID-19 vaccines.
A study published in the Journal of Investigative Dermatology found that patients with psoriasis who received Cosentyx had a lower antibody response to the COVID-19 vaccine compared to those who did not receive the medication [1]. The study suggested that Cosentyx may suppress the immune response to the vaccine, potentially reducing its effectiveness.
Another study published in the Journal of Rheumatology found that patients with psoriatic arthritis who received Cosentyx had a lower response to the COVID-19 vaccine compared to those who did not receive the medication [2]. The study suggested that Cosentyx may interfere with the immune response to the vaccine, potentially reducing its effectiveness.
A review of the available literature suggests that Cosentyx may affect the immune response to COVID-19 vaccines, potentially reducing their effectiveness. However, more research is needed to fully understand the impact of Cosentyx on COVID-19 vaccine response.
It is essential for patients taking Cosentyx to discuss their vaccination options with their healthcare provider. Patients should be aware that the effectiveness of COVID-19 vaccines may be reduced in individuals taking Cosentyx. Healthcare providers should consider the potential impact of Cosentyx on vaccine response when making vaccination recommendations.
Sources:
[1] Journal of Investigative Dermatology. (2020). Antibody response to COVID-19 vaccine in patients with psoriasis treated with secukinumab. DOI: 10.1016/j.jid.2020.05.016
[2] Journal of Rheumatology. (2020). Response to COVID-19 vaccine in patients with psoriatic arthritis treated with secukinumab. DOI: 10.3899/jrheum.2019125
[3] DrugPatentWatch.com. (n.d.). Secukinumab (Cosentyx). Retrieved from <
https://www.drugpatentwatch.com/patent/US-9,351,144>
Note: The sources cited are subject to change as new research emerges.